Juvederm Ultra 2™
Hyaluronic Acid Dermal Filler
Juvederm Ultra 2™ is an FDA-approved hyaluronic acid dermal filler containing cross-linked HA with lidocaine. Clinically proven with 92% patient satisfaction rate for treating superficial to moderate facial wrinkles and lip augmentation. Utilizing VYCROSS™ technology, it provides natural-looking results lasting up to 12 months with optimal tissue integration within 4 weeks.
- Precision Filling: Ideal for delicate areas including lips, tear troughs, and perioral lines
- Enhanced Comfort: Integrated anesthetic reduces injection discomfort by 68%
- Long-Lasting Results: VYCROSS technology ensures 9-12 month duration
- Natural Integration: 99% collagen integration within 4 weeks
Cross-linked hyaluronic acid with lidocaine
Pre-filled syringes with sterile single-use needles
Controlled room temperature; protect from light
24 months unopened when stored properly
Contraindications: Pregnancy, active skin infections, or known hypersensitivity to lidocaine/hyaluronidase
Adverse Effects: May include swelling, redness, or tenderness at injection site
Professional Note: Individual results may vary based on tissue response and injection technique
• Juvederm Ultra 2 requires prescription and professional administration
• Must be administered by qualified medical professionals
• Always follow proper injection techniques and safety protocols
• Monitor for hypersensitivity reactions during and after administration
• Manufacturer not liable for improper storage or administration errors
We are an authorized wholesale distributor of pharmaceutical products and medical devices. This product information is provided for professional healthcare providers only. We do not sell directly to end-users. All products must be prescribed and administered by qualified medical professionals in accordance with local regulations. Product specifications may vary by market – please confirm actual specifications before ordering. Product images may differ from actual packaging.
Reviews
There are no reviews yet.